Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Biomea Fusion, Inc. (Nasdaq: BMEA) announced that its CEO and Chairman will present at the 42nd Annual J.P. Morgan Healthcare Conference and hold 1x1 meetings. A live webcast will be available on the company's website.
01/02/2024 - 04:05 PM
REDWOOD CITY, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced that Thomas Butler, Biomea Fusion’s Chief Executive Officer and Chairman of the Board, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 from 8:15 am – 8:55 am PST, and that Biomea management will hold 1x1 meetings during the conference January 8 – 11.
A live webcast of the presentation will be available on the Investors & Media page of Biomea’s website at: https://investors.biomeafusion.com/news-events/events .
About Biomea Fusion
We are utilizing our proprietary FUSION™ System to discover, design and develop a pipeline of next-generation covalent-binding small molecule medicines designed to maximize clinical benefit for patients with various cancers and metabolic diseases, including diabetes. We aim to cure.
Visit us at biomeafusion.com and follow us on LinkedIn , Twitter and Facebook .
What is the latest announcement from Biomea Fusion, Inc. (Nasdaq: BMEA)?
Biomea Fusion, Inc. (Nasdaq: BMEA) announced that its CEO and Chairman will present at the 42nd Annual J.P. Morgan Healthcare Conference and hold 1x1 meetings.
When will the CEO of Biomea Fusion, Inc. (Nasdaq: BMEA) present at the conference?
The CEO of Biomea Fusion, Inc. (Nasdaq: BMEA) will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 from 8:15 am – 8:55 am PST.
Where can I watch the live webcast of the presentation by Biomea Fusion, Inc. (Nasdaq: BMEA)?
The live webcast of the presentation will be available on the Investors & Media page of Biomea’s website at: https://investors.biomeafusion.com/news-events/events.
BMEA Rankings
#2016 Ranked by Stock Gains
BMEA Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
About BMEA
biomea fusion, llc was formed in 2017 by a small group of biotech executives. we are dedicated to developing innovative medicines for patients. it is our goal to design and clinically develop patient friendly therapies with higher efficacy than the current standard of care. the more precise a therapeutic agent is, the better the potential outcomes for individual patients’ needs. we are a precision oncology company developing novel small molecules that target aggressive forms of cancer. patients with these aggressive tumors typically exhibit high mortality rates and suffer from inadequate treatment options. with our current program, we are targeting specific changes to the dna of patients, which can be isolated as key drivers for tumor growth. we leverage our internal expertise and compliment it with computational drug design technology to build novel medicines for the future. we have significantly invested in the upfront development of our targeted therapies and are conducting bro
